Abrdn Life Sciences Investors HQL FINANCIAL
Company Overview
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Why Investors Should Care
Generates a return on equity of 41.4%, reflecting efficient use of shareholder capital.
Trades at a P/E of 3.1, below the sector median of 12.9.
Offers a dividend yield of 11.54%.
Recent Developments
- Sep 2025 Revenue of $86.39M (-0.3% YoY); net profit $85.59M.
- Trailing 12 Months Year-on-year growth — revenue -60.8%, earnings +0.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -60.80% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 0.35% |
Stock Price Performance
| 1 Year: | +70.49% |
| 6 Months: | +33.98% |
| 3 Months: | +26.85% |
| 1 Month: | +2.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.37 · Neutral
P/E of 3.10 is below the sector median of 12.89 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 41.4%.
- Attractive dividend yield of 11.54%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Financial Services).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HQL Abrdn Life Sciences Investors FINANCIAL | 20.56 | 3.10 | $625.19M | 11.54% | - | 41.42% | - | - |
| 2 | JPM JPMorgan Chase & Co. SPXR3KFINANCIAL | 353.51 | 15.15 | $939.70B | 1.72% | - | 17.79% | 12.50% | 14.83% |
| 3 | BRK-B Berkshire Hathaway Inc. SPXFINANCIAL | 505.83 | 12.72 | $712.23B | 0.00% | - | 12.12% | 4.18% | 9.44% |
| 4 | V Visa Inc. SPXR3KFINANCIAL | 368.64 | 31.35 | $628.20B | 0.72% | 37.15% | 61.19% | 14.33% | 13.04% |
| 5 | MA Mastercard Incorporated SPXR3KFINANCIAL | 570.89 | 31.44 | $496.37B | 0.62% | 60.19% | - | 12.29% | 19.21% |
| 6 | BAC Bank of America Corporation SPXR3KFINANCIAL | 62.39 | 14.41 | $436.28B | 2.04% | - | 11.20% | 3.14% | 4.27% |
| 7 | BRK-A Berkshire Hathaway Inc. FINANCIAL | 757,791.00 | 12.71 | $370.14B | 0.00% | - | 12.12% | 7.60% | 10.02% |
| 8 | HSBC HSBC Holdings plc FINANCIAL | 106.26 | 15.18 | $363.70B | 3.65% | - | 13.10% | 9.75% | 12.72% |
| 9 | MS Morgan Stanley SPXR3KFINANCIAL | 216.24 | 17.48 | $339.62B | 2.26% | - | 17.97% | 3.76% | 9.66% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|
| Revenue | -103.25M | 23.52M | 86.69M | 86.39M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 1.35M | 1.17M | 1.39M | 791.57K |
| Operating Income | - | - | - | - |
| EBITDA | - | - | - | - |
| Interest Expense | - | - | - | - |
| Pretax Income | -104.60M | 22.35M | 85.30M | 85.59M |
| Tax Provision | - | - | - | - |
| Net Income | -104.60M | 22.35M | 85.30M | 85.59M |
| Diluted EPS | -4.26 | 0.79 | 3.04 | 2.79 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 414.73M | 402.60M | 460.58M | 515.38M |
| Current Assets | - | - | - | - | - |
| Cash & Equivalents | - | 445 | 477 | 1 | 75.54K |
| Inventory | - | - | - | - | - |
| Receivables | - | 623.47K | 5.04M | 231.11K | 1.14M |
| Total Liabilities | - | 16.82M | 666.96K | 888.61K | 1.73M |
| Current Liabilities | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
| Total Equity | - | 397.90M | 401.93M | 459.69M | 513.66M |
| Shares Outstanding | - | 25.68M | 26.79M | 28.06M | 29.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2025 |
|---|---|
| Operating Cash Flow | 31.71M |
| Investing Cash Flow | - |
| Financing Cash Flow | -31.63M |
| Capital Expenditure | - |
| Free Cash Flow | 31.71M |
| Net Change in Cash | 75.54K |
Ratios (Annual)
Figures in %.
| Metric | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | 101.3% | 95.0% | 98.4% | 99.1% |
| ROE % | -26.3% | 5.6% | 18.6% | 16.7% |
| ROCE % | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Morgan Stanley | 5.83% | 1.77M | $34.39M |
| 2 | Penserra Capital Management LLC | 2.76% | 838.89K | $16.28M |
| 3 | Raymond James Financial, Inc. | 2.27% | 689.13K | $13.38M |
| 4 | LPL Financial LLC | 1.69% | 514.16K | $9.98M |
| 5 | Allspring Global Investments Holdings, LLC | 1.50% | 455.12K | $8.83M |
| 6 | Needham Investment Management, L.L.C. | 1.46% | 443.04K | $8.60M |
| 7 | Flagship Harbor Advisors, LLC | 1.32% | 400.76K | $7.78M |
| 8 | Ameriprise Financial, Inc. | 0.64% | 195.45K | $3.79M |
| 9 | Advisors Asset Management, Inc. | 0.56% | 169.81K | $3.30M |
| 10 | Formidable Asset Management, Llc | 0.54% | 165.24K | $3.21M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HQL
Price to earnings forward of abrdn Life Sciences Investors Shares of Beneficial Interest – NYSE:HQL - tradingview.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQX0YxeXRFdzNlenhzNUsyc2xpRkFvU0xFTktTcng2eTQtNDNGQTY2ZXhuM29PcWtTbl9OX1BsTWxDZmxVSnVaUE83bFpJdHBBZVBRZUxNbzJjc01kTXhYRjdBOVg3ZzRla1o0VWhsbXZXUTJhNjNGaUZLaGtaMGVyUkdIVmFCNDV2TUZCa3…
Insider Purchase: Director at $HQL Buys 527 Shares | HQL Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPc2RuRmlDZHhKMDBwa2I2ZUVIQ2dVbWswdnBtWjd0dE5oUWoyeFdHWklQQzBNdXNYUmkwUm5OcXc2a3dSdHlVOEZaNFdiM1NzMV9Sc1JSeEd5TGdVLVJqN002WGRaOU9vclQ3OFZ4X0hFaHdEZFhmcWdjQmtGcUFVSDZVVUsxVlRFd2x6b2…
abrdn Life Sciences Investors $HQL Shares Sold by Rivernorth Capital Management LLC - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOWkVMZExnVTBLVTJqNXB2WGlEa1lvWUdVczNfMmY1blJxOEF6SGd0UTFISGtzekpfUWJRclp6Mjh5Mk16SzBtUFdOM1VmaW4xUU9IUGlYMW9Sa1RKQWs2QjVkMWhFeU01VHZNRTZoVl81WFNzdF9BZ3l2Q2llVWJVZFVpdXhIclNibXB5UF…
Director Chris Mahai buys 527 abrdn Life Sciences (NYSE: HQL) shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOTlgwWWtrQ0U0dUVyQllXOVlHTWRmQjlaMHFrRWdXa3d4RjhGWldhM2JHLXZqN2xVMS1sajF0bzJlT01rUlB5bDBFaWtNQVYta2ZQTzVzS2x4MWtkWWsxTG1zajRrLThsdld3eHBJekRyQ3EwdUtiTVYxWHVwVTN4cVFuY2dYRzA5R2hBTX…
TeklaLife Sciences Investors (HQL) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPYkhvNC12a0lGX3cyc2VaY21YeEhzd2MwWXJIU3pGSHhqcDlBdlFLdDk3S3o1WjhuUWZoSDdJalEtQl9zN19hTldDbUdJWDEtNThhaWFyZ0NOLVUyWWU4TnNqbFpNRTVRQVFkeGZ6OXRxbTR5b3R5d2haS0hJQ1VxT3lNa0JsSzdyd1J0dT…
Abrdn Life Sciences Investors Q2 2026 Commentary (HQL) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOczBsSGJJRTZ4Z1QwTXNzSm5QeXBSNmdvdi1wa0l2Nmx2Sks0QmljTlVNWHZramltMnFmMzZpZElmQXFmQWhYdVFCUFZ4SWZWQW1uQ1oxSXV4MFVxNlUwWHhGSWdqaDdQc3VXeU1MRG13SFdZb3doa3BtZHJkeFhtV1hFLWZvNlNDSDNKRk…
HQL — Frequently Asked Questions
What is the current share price of Abrdn Life Sciences Investors (HQL)?
As of 2026-09-19 21:16 PDT, Abrdn Life Sciences Investors (HQL) trades at $20.56 on NYSE. Its 52-week range is $12.04 to $22.04.
What is the market capitalisation of HQL?
Abrdn Life Sciences Investors (HQL) has a market capitalisation of $625.19M on NYSE.
What is the P/E ratio of HQL?
HQL trades at a trailing price-to-earnings (P/E) ratio of 3.10. The industry average P/E is 12.89. Its price-to-book (P/B) ratio is 1.05.
Does HQL pay a dividend?
Abrdn Life Sciences Investors (HQL) currently offers a dividend yield of 11.54%.
What is the return on equity (ROE) of HQL?
HQL has a return on equity (ROE) of 41.42%.
Is HQL a good stock to buy?
This page provides a data-driven analysis of Abrdn Life Sciences Investors (HQL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.